Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Janux Therapeutics director Jake Simson reported equity awards tied to his board service. He received 5,500 restricted stock units, each representing one share of common stock, vesting on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service. He was also granted options for 15,500 shares at an exercise price of $13.66 per share, vesting in equal monthly installments over the 12 months following June 11, 2026 and fully vested by the next annual meeting, subject to continued service. After these awards, his reported direct common stock holdings total 11,750 shares. Under an arrangement with RA Capital Management, these RSUs and options are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and Simson is obligated to turn over any net stock or cash received, so he disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Simson Jake
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,500 | $0.00 | -- |
| Grant/Award | Common Stock | 5,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 15,500 shares (Direct, null);
Common Stock — 11,750 shares (Direct, null)
Footnotes (1)
- Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
Key Figures
RSU grant: 5,500 units
Option grant size: 15,500 shares
Option exercise price: $13.66 per share
+3 more
6 metrics
RSU grant
5,500 units
Each RSU represents one share of common stock
Option grant size
15,500 shares
Stock options on common stock
Option exercise price
$13.66 per share
Exercise price for 15,500 stock options
Option expiration
June 10, 2036
Expiration date of granted stock options
Shares held after transaction
11,750 shares
Direct common stock holdings following reported awards
RSU vesting date
June 11, 2027 or next annual meeting
RSUs vest on earlier of these dates, subject to service
Key Terms
restricted stock units ("RSUs"), beneficial ownership, advisory fees, continuous service
4 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
advisory fees financial
"which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor"
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
continuous service financial
"subject to the Reporting Person's continuous service on such date"
FAQ
What equity awards did Janux Therapeutics (JANX) director Jake Simson report?
Jake Simson reported a grant of 5,500 restricted stock units and stock options for 15,500 shares at a $13.66 exercise price. Both awards relate to his board service and follow specified vesting schedules tied to future dates and continued service.
How do the RSUs granted to Jake Simson at Janux Therapeutics (JANX) vest?
The 5,500 RSUs vest on the earlier of June 11, 2027 or the date of the next annual stockholder meeting. Vesting requires Simson’s continuous service through that date, meaning he must remain in his role until the vesting trigger occurs.
What are the terms of the stock options granted to Jake Simson at Janux Therapeutics (JANX)?
Simson received options for 15,500 shares of common stock at a $13.66 exercise price, expiring June 10, 2036. The options vest in equal monthly installments over 12 months after June 11, 2026, and will be fully vested by the next annual stockholder meeting.
Does Jake Simson personally benefit from the Janux Therapeutics (JANX) RSU and option grants?
According to the disclosure, Simson holds the RSUs and options for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II. He must turn over any net stock or cash received, offsetting advisory fees, and therefore disclaims beneficial ownership.
How is RA Capital Management involved in Jake Simson’s Janux Therapeutics (JANX) awards?
The awards are subject to an arrangement with RA Capital Management. Simson holds the RSUs and options for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II and must deliver net proceeds, which reduce advisory fees owed to RA Capital.